Travis, W. D. et al. An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am. J. Respir. Crit. Care Med. 188, 733–748 (2013).

Article  PubMed  PubMed Central  Google Scholar 

Luppi, F. et al. Lung complications of Sjogren syndrome. Eur. Respir. Rev. 29, 200021 (2020).

Article  PubMed  PubMed Central  Google Scholar 

Johnson, S. R. et al. 2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) guideline for the screening and monitoring of interstitial lung disease in people with systemic autoimmune rheumatic diseases. Arthritis Rheumatol. 76, 1201–1213 (2024).

Article  PubMed  Google Scholar 

Johnson, S. R. et al. 2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) guideline for the treatment of interstitial lung disease in people with systemic autoimmune rheumatic diseases. Arthritis Rheumatol. 76, 1182–1200 (2024).

Article  PubMed  Google Scholar 

Flaherty, K. R. et al. Nintedanib in progressive fibrosing interstitial lung diseases. N. Engl. J. Med. 381, 1718–1727 (2019).

Article  CAS  PubMed  Google Scholar 

Levi, Y. et al. Rheumatological assessment is important for interstitial lung disease diagnosis. J. Rheumatol. 45, 1509–1514 (2018).

Article  PubMed  Google Scholar 

Fischer, A. & Du Bois, R. M. Interstitial lung disease in connective tissue disorders. Lancet 380, 689–698 (2012).

Article  PubMed  Google Scholar 

Du Bois, R. M. et al. 6-minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis. Eur. Respir. J. 43, 1421–1429 (2014).

Article  PubMed  Google Scholar 

Matteson, E. L. et al. Nintedanib in patients with autoimmune disease-related progressive fibrosing interstitial lung diseases: subgroup analysis of the INBUILD trial. Arthritis Rheumatol. 74, 1039–1047 (2022).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Solomon, J. J. et al. Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 study. Lancet Respir. Med. 11, 87–96 (2023).

Article  CAS  PubMed  Google Scholar